New method for the purification of Factor VIII VIII/FVW concentrate study published on
The study Progress in large-scale purification of Factor VIII/von Willebrand factor concentrates using ion-exchange chromatographyhas been published on “Vox Sanguinis” (2008) 95, 298–307, Entirely conducted by Kedrion’s researchers, the study presents the results of the development of a new purification method for a Factor VIII/von Willebrand Factor concentrate. A process scale-up is now being investigated
Viral Risk Assessment: Kedrion wins the SIMTI award
As part of the XXXVIII National Conference on Transfusion Medicine, the Scientific Committee of SIMTI (Italian Society of Transfusion and Immunohaematologic Medicine) has selected, as the winner for the session “transfusion-transmitted diseases”, the presentation Viral Risk Assessment – Modello Kedrion: applicazione nell’ambito del plasma italiano destinato alla lavorazione industriale (Viral Risk Assessment – Kedrion’s model:
Four new departments in the Bolognana site. Investiments in continuous plant and process improvement Keep Flowing
The investments for the continuous improvement of the manufacturing processes and plants of Kedrion are going on at a fast pace. After passing the AIFA inspection (AIFA is the Italian Drugs Agency) and proving to comply with international Good Manufacturing Practices (GMP), the process for the authorisation to operate with four new departments in the
Agreement between Kedrion and ProMetic for the development of Hyperimmune products
Kedrion S.p.A. and ProMetic Life Sciences Inc. (TSX:PLI) announced that they have signed the definitive agreement for two hyperimmunes. The first product to be developed will target the Hepatitis B Hyperimmune. Kedrion has in-licensed ProMetic’s technologies for the manufacturing of hyperimmune products in Europe. Royalties, licensing and service fees for the sales of products in
Visit of the Minister of reform and innovation in the Public Administration, Luigi Nicolais, to the Kedrion plant in Sant’Antimo (Naples)
The Minister of Reform and Innovation in the Public Administration, Luigi Nicolais, recently visited the Kedrion plant for the production of plasma-derived products in Sant’Antimo, near Naples. Kedrion Group, specialising in the production and distribution of pharmaceutical products derived from plasma proteins, has a total of three production plants: in addition to the one in
Paolo Marcucci has joined PPTA’s Global Board of Directors
Paolo Marcucci, President and CEO of Kedrion, has joined the Global Board of Directors of the Plasma Protein Therapeutics Association (PPTA). “We are excited that Mr. Marcucci is joining the Global Board of Directors” said Jan M. Bult, PPTA’s President. “Paolo Marcucci understands the many challenges confronting our industry and the patients we serve. He
European GMP, current issues and future developments: Kedrion in the organising committee of the EMA / PDA Joint Conference
Kedrion (Italy) is the only company working in the plasma derivatives industry which is sitting on the organising committee of the EMEA/PDA (Parenteral Drug Association) Joint Conference. The company appointed Claudia Nardini, in charge of Industrial Development and Research for the company and deputy president of the Italian chapter of the PDA, as its delegate;
Production of plasma-derived products to highest international quality standards: Kedrion technology for the new Moscow plant
Kedrion embarks on its second technology transfer to Russia following the one in Kirov, by signing an agreement in Moscow for the development of a plasma-derivatives production plant to the highest international quality, safety and efficiency standards. The agreement signed between Kedrion, the Dutch company BTI and the Moscow Government covers both the engineering operations
Kedrion buys a production plant in Hungary from Teva Pharmaceutical Industries Ltd
Kedrion SpA has bought yesterday from Teva Pharmaceutical Industries Ltd (a leading global pharmaceutical company) 100% of the shares in Human Bioplazma Manufacturing and Trading Ltd, a company established under the Hungarian law and based in Gödöllo (Budapest). Kedrion thus acquires a manpower of 127 employees, a fractionation and production plant with a productive capacity
Kedrion stakes on “vertical integration”, two agreements signed to buy four plasma collection centres in the USA and Germany
Kedrion has recently finalised two important agreements for the purchase of four plasma collection centres, two in the United States (Florida and Alabama) and two in Germany (Bavaria). The agreement to buy the two US centres, Pensacola (Florida) and Mobile (Alabama), has been signed with Life Therapeutics, a leader in plasma collection for therapeutic and